Fig. 1: Clinically relevant oncology combination screen (CROCS) on primary MPM patient samples using HTDBP to identify hits. | Nature Communications

Fig. 1: Clinically relevant oncology combination screen (CROCS) on primary MPM patient samples using HTDBP to identify hits.

From: Dynamic BH3 profiling identifies pro-apoptotic drug combinations for the treatment of malignant pleural mesothelioma

Fig. 1: Clinically relevant oncology combination screen (CROCS) on primary MPM patient samples using HTDBP to identify hits.The alternative text for this image may have been generated using AI.

Fresh primary MPM patient samples were dissociated, treated with CROCS and HTDBP carried out. Cells were analyzed by immunofluorescence microscopy and Z-score was calculated to identify drug/drug combinations that prime tumor cells. a Schematic showing the workflow for measuring drug-induced priming using HTDBP on primary MPM patient samples. Created with BioRender.com. b Graphs show mean Z-score for each drug treatment (carried out in duplicate), for each primary MPM patient sample (MPS). Each individual dot represents a different drug treatment (single agent or drug-drug combination). A red dot represents a hit with a Z-score ≥ 3 with no replicate <1.5. Black dots are non-hits. c Graph showing the mean Z-score correlation between two tumor samples from the same patient (MPS:L and MPS:M) using one-tailed Spearman ranked test (p value = <0.0001). MPS:L is a tumor from the 7th rib and MPS:M is a pleural tumor. d Venn diagram showing the overlap between the CROCS HTDBP hits (red dots in part b) for MPS:L and MPS:M.

Back to article page